WuXi PharmaTech Announces Third Quarter 20...( Note 1: Eight (8) ordinary sha...),Health

WUXI PHARMATECH (CAYMAN) INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006

(in thousands of US dollars, except ADS data and per ADS data)

(Unaudited )

Three Months Ended Nine Months Ended

September 30, September 30,

2007 2006 2007 2006

Net revenues:

Laboratory services 26,744 16,808 73,539 38,102

Manufacturing 7,305 2,343 24,572 8,993

Total net revenues 34,049 19,151 98,111 47,095

Cost of revenues:

Laboratory services (13,843) (8,024) (36,499) (17,329)

Manufacturing (4,206) (2,056) (14,666) (8,257)

Total cost of revenues (18,049) (10,080) (51,165) (25,586)

Gross Profit 16,000 9,071 46,946 21,509

Operating expenses:

Selling and marketing

expenses (468) (554) (1,683) (1,198)

General and administrative

expenses (8,032) (5,599) (24,415) (14,382)

Total operating expenses (8,500) (6,153) (26,098) (15,580)

Operating income 7,500 2,918 20,848 5,929

Other income (expenses),

net:

Other income (expenses),

net (9) 141 842 108

Interest income

(expenses), net 1,334 (199) 589 (821)

Total other income

(expenses), net 1,325 (58
'/>"/>